About Us
A message from the founder of LightWeightMD, Dr. Henry Igdal:
​
I have been practicing Internal Medicine since 1986 and Nephrology since 1991.Both disciplines have afforded me great insight and patient experience managing Diabetes, Hypertension, Cardiovascular and Chronic Renal Disease. I have managed in my career more Hemodialysis patients than you can imagine and I am intimately familiar with the complex medical issues that arise from complications stemming from these serious chronic diseases. Having here-and-now medical strategies and therapies that can reduce and influence the morbidity and mortality associated with these disease states is a revolutionary concept.
In the next few years newer cutting edge GLP-1 and GIP agents will be developed, currently being researched and tested, that will further benefit the management of chronic Obesity and add to the already available therapies. I plan to be on the cutting edge of understanding and utilizing these therapies to help patients safely and effectively navigate the challenges of weight loss. It is for these reasons that I have begun this journey creating LightWeightMD.
Our mission statement at LightWeightMD is to educate and simplify the way individuals gain access to newer GLP-1 weight loss medications. We utilize affordable and convenient GLP-1 compounded medications, delivered directly to your home. Our top priority is providing personalized customer service, transparency, and ease of access to our patients. Obesity is a growing health problem in the US affecting greater than 25% of our population. Millions of Americans already use the popular GLP-1 injectable treatments. Wegovy is the first ever weight loss medication to gain expanded approval for Obesity, recently approved by the FDA. This demonstrates that weight loss drugs have significant health benefits beyond shedding unwanted pounds and regulating blood sugar.
Weekly injections of Wegovy reduce the overall risk of heart attack, stroke and death from cardiovascular disease by 20% according to a recent landmark late-stage trail of the drug. Adults with obesity and heart disease are at increased risk of those cardiovascular complications, so providing a treatment option that is proven to lower that is a major advance in public health. In March Novo Nordisk reported late-stage trial results showing that Ozempic cut the risk of kidney disease progression and death from kidney and cardiovascular complications by 24% in diabetic patients with chronic kidney disease. The results added to the mounting evidence of the broader health benefits associated with Ozempic and similar drugs, beyond weight loss and type II diabetes treatment.
​
I founded LightWeightMD with a commitment to connect people with the medicines they need at more affordable rates. I understand the profound impact that weight and other chronic conditions can have on your life, and I am dedicated to helping you achieve your health goals with compassion and personalized care. Together we will ensure you receive the best possible care every step of the way and meet your goals and celebrate your milestones.
​
Sincerely,
Henry Igdal M.D.